Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990–2022. J Am Coll Cardiol. 2023;82:2350–473. https://doi.org/10.1016/J.JACC.2023.11.007.

Article  PubMed  Google Scholar 

Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93-621. https://doi.org/10.1161/CIR.0000000000001123.

Article  PubMed  Google Scholar 

Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1555–66. https://doi.org/10.1177/2047487317715769.

Article  PubMed  PubMed Central  Google Scholar 

Zafeiropoulos S, Doundoulakis I, Bekiaridou A, et al. Rhythm vs rate control strategy for atrial fibrillation: a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol. 2024. https://doi.org/10.1016/j.jacep.2024.03.006.

Article  PubMed  Google Scholar 

Marrouche NF, Brachmann J. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol. 2009;32:987–94. https://doi.org/10.1111/j.1540-8159.2009.02428.x.

Article  PubMed  Google Scholar 

Turagam MK, Musikantow D, Whang W, et al. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials. JAMA Cardiol. 2021;6:697–705. https://doi.org/10.1001/jamacardio.2021.0852.

Article  PubMed  Google Scholar 

Al-Khatib SM, Benjamin EJ, Buxton AE, et al. Research needs and priorities for catheter ablation of atrial fibrillation: a report from a national heart, lung, and blood institute virtual workshop. Circulation. 2020;141:482–92. https://doi.org/10.1161/CIRCULATIONAHA.119.042706.

Article  PubMed  Google Scholar 

Singh S, Garg A, Tantry US, Bliden K, Gurbel PA, Gulati M. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. Curr Probl Cardiol. 2024;49: 102403. https://doi.org/10.1016/j.cpcardiol.2024.102403.

Article  PubMed  Google Scholar 

Lavalle Cobo A, Masson W, Lobo M, et al. Ethnic/racial and geographic disparities on major cardiovascular events in glucagon like peptide-1 receptor agonists trials: a meta-analysis. Curr Probl Cardiol. 2023;48: 101940. https://doi.org/10.1016/j.cpcardiol.2023.101940.

Article  PubMed  Google Scholar 

Merza N, Akram M, Mengal A, et al. The safety and efficacy of GLP-1 receptor agonists in heart failure patients: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48:101602. https://doi.org/10.1016/j.cpcardiol.2023.101602.

Article  PubMed  Google Scholar 

Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21)00203-5.

Article  CAS  PubMed  Google Scholar 

Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192.

Article  CAS  PubMed  Google Scholar 

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66. https://doi.org/10.1007/S00125-022-05787-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1–156. https://doi.org/10.1161/CIR.0000000000001193.

Article  PubMed  Google Scholar 

Peigh G, Wasserlauf J, Vogel K, et al. Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32:2097–104. https://doi.org/10.1111/jce.15141.

Article  PubMed  PubMed Central  Google Scholar 

Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training. https://training.cochrane.org/handbook/current. Accessed Jan 17, 2023.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https://doi.org/10.1136/BMJ.N71.

Article  PubMed  PubMed Central  Google Scholar 

Haddaway NR, Grainger MJ, Gray CT. Citationchaser: an R package and Shiny app for forward and backward citations chasing in academic searching 2021. https://doi.org/10.5281/ZENODO.4543513.

Ottawa Hospital Research Institute. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Jan 17, 2023.

Zou F, Freilich M, Ammirati G, et al. MP-483498-003 semaglutide and atrial fibrillation recurrence after catheter ablation. Hear Rhythm. 2024;21:S113–4. https://doi.org/10.1016/j.hrthm.2024.03.1802.

Article  Google Scholar 

Watkins C, Bennett I. A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data. Res Synth Methods. 2018;9:352–60. https://doi.org/10.1002/JRSM.1301.

Article  PubMed  Google Scholar 

Satti DI, Karius A, Chan JSK, et al. Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation. JACC Clin Electrophysiol. 2024. https://doi.org/10.1016/j.jacep.2024.03.031.

Article  PubMed  Google Scholar 

Tabaja C, Younis A, Wass SY, et al. PO-05-145 glucagon-like peptide-1 receptor agonist in patients undergoing atrial fibrillation ablation: a matched analysis. Hear Rhythm. 2024;21:S542. https://doi.org/10.1016/j.hrthm.2024.03.1380.

Article  Google Scholar 

Sheth A, Patel H, Kowlgi GN, et al. CE-482907-002 impact of GLP-1 agonists in patients with atrial fibrillation ablation. Hear Rhythm. 2024;21:S41–2. https://doi.org/10.1016/j.hrthm.2024.03.334.

Article  Google Scholar 

Stachteas P, Karakasis P, Karagiannidis E, et al. Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing atrial fibrillation recurrence after catheter ablation. Hellenic J Cardiol. 2024. https://doi.org/10.1016/j.hjc.2024.03.008.

Article  PubMed  Google Scholar 

Shi W, Zhang W, Zhang D, et al. Comparison of the effect of glucose-lowering agents on the risk of atrial fibrillation: a network meta-analysis. Hear Rhythm. 2021;18:1090–6. https://doi.org/10.1016/j.hrthm.2021.03.007.

Article  Google Scholar 

Wei J, Wang R, Ye H, Wang Y, Wang L, Zhang X. Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13: 910256. https://doi.org/10.3389/fendo.2022.910256.

Article  PubMed  Google Scholar 

World Obesity Atlas 2023 | World Obesity Federation. https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023. Accessed Jun 9, 2024.

Li W, Wang Y, Zhong G. Glycemic variability and the risk of atrial fibrillation: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1126581. https://doi.org/10.3389/fendo.2023.1126581.

Article  PubMed  Google Scholar 

Kim D, Yang P-S, Joung B. Optimal rhythm control strategy in patients with atrial fibrillation. Korean Circ J. 2022;52:496–512. https://doi.org/10.4070/kcj.2022.0078.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–803. https://doi.org/10.1161/CIRCRESAHA.114.301958.

Article  CAS  PubMed  Google Scholar 

Bohne LJ, Jansen HJ, Dorey TW, et al. Glucagon-like peptide-1 protects against atrial fibrillation and atrial remodeling in type 2 diabetic mice. JACC Basic Transl Sci. 2023;8:922–36. https://doi.org/10.1016/j.jacbts.2023.01.005.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Parajuli KR, Fava GE, et al. GLP-1 receptor in pancreatic α-cells regulates glucagon secretion in a glucose-dependent bidirectional manner. Diabetes. 2019;68:34–44. https://doi.org/10.2337/db18-0317.

Article  CAS